<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196062</url>
  </required_header>
  <id_info>
    <org_study_id>CRE Ref. No. 2019.331</org_study_id>
    <nct_id>NCT04196062</nct_id>
  </id_info>
  <brief_title>EndoMaster EASE System for Treatment of Colorectal Lesions</brief_title>
  <acronym>MASTERCESD</acronym>
  <official_title>Prospective, Single Arm Study to Assess the Safety and Performance of the EndoMaster EASE System for the Treatment of Colorectal Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single arm study to assess the safety and performance of the&#xD;
      EndoMaster EASE (Endoluminal Access Surgical Efficacy) System for the treatment of patients&#xD;
      with colorectal neoplasms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single arm study to assess the safety and performance of robotically assisted&#xD;
      ESD of superficial colorectal lesions, that otherwise cannot be optimally and radically&#xD;
      removed by snare-based techniques&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, Single-Arm Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete (R0) resection</measure>
    <time_frame>30 days</time_frame>
    <description>rate of complete (R0) resection defined as en bloc, one-piece resection with histologically confirmed tumour-free lateral and vertical margins</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding during or after the procedure</measure>
    <time_frame>30 days</time_frame>
    <description>Bleeding as evidence by&#xD;
Active bleeding during the robotic ESD procedure&#xD;
Bleeding after ESD with clinical evidence of 1. Fresh hematemesis; 2. Passage of tarry stool with pulse &gt; 100 or systolic blood pressure &lt; 100; 3. Drop in hemoglobin level of &gt; 4 g/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perforation</measure>
    <time_frame>30 days</time_frame>
    <description>Perforation at the ESD site as assessed by endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjunctive procedures to control bleeding</measure>
    <time_frame>1 day</time_frame>
    <description>Use of coagrapser / clips</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical sepsis with changes in inflammatory markers as evidence by&#xD;
clinical symptoms of fever, pulse &gt; 100&#xD;
radiological evidence of intraperitoneal collection&#xD;
elevated WBC count of &gt; 10.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impairment of renal function</measure>
    <time_frame>30 days</time_frame>
    <description>renal failure as evidence of derangement of renal function with elevated creatinin level &gt; 100 mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Serous Adverse Events at preocedure and through discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of procedure</measure>
    <time_frame>1 day</time_frame>
    <description>OT time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operator assessment of device performance</measure>
    <time_frame>1 day</time_frame>
    <description>Operator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device deficiencies</measure>
    <time_frame>1 day</time_frame>
    <description>Device malfunction and Use errors during the ESD procedure as evidence by&#xD;
cessation of the function of the EndoMASTER EASE system&#xD;
need to use of the immediate cessation button for the EndoMASTER EASE system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Length of Hospital Stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology of resected specimen</measure>
    <time_frame>30 days</time_frame>
    <description>En bloc resection rate / R0 rate / positive vertical margin / positive lateral margin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonoscopy followup</measure>
    <time_frame>6 months, 18 months to 3 years</time_frame>
    <description>Healing of operative site / presence of suspicious tissue for biopsy / presence of stricture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer status by cross-sectional imaging (MRI / CT)</measure>
    <time_frame>12 months and 3 years</time_frame>
    <description>local recurrence / recurrence at different site in colon / metastatic disease and location</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>30 days</time_frame>
    <description>en bloc, one-piece excision of the neoplasm irrespective of histopathology, in the absence of device-related SAE through 30 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Colonic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Robotic ESD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of early colorectal neoplasia / lateral spreading tumors by ESD using EndoMASTER EASE robotic system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoMASTER EASE Robotic system for ESD</intervention_name>
    <description>EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery</description>
    <arm_group_label>Robotic ESD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 85;&#xD;
&#xD;
          2. Suspected intramucosal neoplasm of the colon or rectum, including adenocarcinoma and&#xD;
             tubular, tubulovillous, or villous adenomas.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Informed consent not available;&#xD;
&#xD;
          2. Carcinoma of colon or rectum with known involvement beyond the submucosa;&#xD;
&#xD;
          3. Evidence of distant spread of colon cancer;&#xD;
&#xD;
          4. Presence of another active malignancy;&#xD;
&#xD;
          5. Pregnancy;&#xD;
&#xD;
          6. Patients considered unfit for general anaesthesia;&#xD;
&#xD;
          7. The endoscopic platform cannot reach the target site;&#xD;
&#xD;
          8. Current participation in another clinical research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Chiu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Wai Yan Chiu, MD, FRCSEd</last_name>
    <phone>+85235053952</phone>
    <email>philipchiu@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Man Yee Yung</last_name>
    <phone>+85235052956</phone>
    <email>myyung@surgery.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Combined Endoscopy Center, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>00000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Chiu, MD</last_name>
      <phone>85226322627</phone>
      <email>philipchiu@surgery.cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Man Yee Yung</last_name>
      <phone>+85235052956</phone>
      <email>myyung@surgery.cuhk.edu.hk</email>
    </contact_backup>
    <investigator>
      <last_name>Philip WY Chiu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Philip Wai Yan CHIU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Colonic ESD</keyword>
  <keyword>Robotic Endoscope</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

